Background: A predominance of melanomas on the left side of the body has recently been described. No associations between tumour laterality and gender, age or anatomical site have been identified.
Aim: The aim of this study was to investigate the prevalence of left-sided melanomas in an Irish population and to examine potential associations with various patient and tumour characteristics.
Methods: A retrospective chart review of patients with cutaneous melanoma who were treated over a 10-year period was carried out. Lateral distribution of melanoma on either side of the body was compared using χ(2) analysis and evaluated by gender, age group, anatomic location, histologic subtype and Breslow depth.
Results: More melanomas occurred on the left side (57%, P = 0.015), and this finding was particularly significant in females. For both genders combined, there were no statistically significant differences in laterality by age group, anatomic location, type of melanoma and Breslow depth. There were significantly more superficial spreading melanomas on the left side in both men and women.
Conclusions: This study demonstrates a predominance of left-sided melanomas in Irish patients. While a number of demographic and molecular associations have been proposed, further research is required to fully explain this phenomenon.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11845-011-0713-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring Potential Orbital Metastatic Pathways in Sinonasal Mucosal Melanoma: A Case Report.
Case Rep Otolaryngol
November 2024
Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
The following case potentially provides insight into the mechanisms of lymphogenic metastasis in sinonasal cancer. A 63-year-old patient who presented with progressive diplopia and left-sided periocular pain was diagnosed with a cT4bN0M0 mucosal melanoma of the ethmoid sinus. She underwent a combined endonasal and transcranial tumor resection, and an orbital exenteration.
View Article and Find Full Text PDFPosterior retroperitoneal adrenalectomy for metastatic disease: a multi-site Australian series.
ANZ J Surg
November 2024
Surgical Services, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
Background: Posterior retroperitoneoscopic adrenalectomy (PRA) for isolated adrenal metastasis is minimally invasive, may prolong survival and improve quality of life. The current evidence base is scant.
Methods: A multi-site retrospective analysis of all cases of PRA for adrenal metastasis between 2011 and 2023, by four high-volume adrenal surgeons was performed.
Melanoma of Unknown Primary With Metastasis to the Brain: A Case Report and Review of the Literature.
Cureus
August 2024
Neurosurgery, Desert Regional Medical Center, Palm Springs, USA.
We present the case of a 72-year-old male found to have melanoma of unknown primary (MUP) in the lung with brain metastasis. The patient has a history of prostate cancer with radical proctectomy in 1999, hypertension with right-sided heart failure, and bilateral cataracts treated operatively. He presented to their home hospital after an unwitnessed fall, with a history of left-sided weakness.
View Article and Find Full Text PDFThe risk of ultraviolet exposure for melanoma in Fitzpatrick skin types I-IV: A 20-year systematic review with meta-analysis for sunburns.
J Eur Acad Dermatol Venereol
September 2024
Department of Dermatology, Henry Ford Health, Detroit, Michigan, USA.
Article Synopsis
- A systematic review was conducted to analyze the relationship between different types of ultraviolet (UV) exposure and the risk of melanoma in individuals with Fitzpatrick skin types I-IV over the past 20 years.
- Out of nearly 20,000 studies, 26 were included, and a significant association between UV exposure and melanoma was found in 77% of these studies, particularly highlighting sunburn as a key risk factor.
- The research indicates that UV exposure remains a critical modifiable risk factor for melanoma in fair-skinned individuals, with specific odds ratios demonstrating the increased risk associated with sunburn and cumulative sun exposure.
Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma.
J Immunother Cancer
July 2024
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Background: Lymphocyte activation gene 3 (LAG-3) is expressed on activated immune cells and has emerged as a promising target for immune checkpoints blockade. However, conflicting findings have been reported regarding the association between LAG-3 expression in tumors and patient prognosis, indicating the need for further investigation into the significance of LAG-3 expression levels in tumor therapies. In this study, Ga-NOTA-XH05, a novel peptide-based positron emission tomography (PET) tracer targeting LAG-3, was constructed to non-invasively detect LAG-3 expression in melanoma after CpG oligonucleotide (CpG) treatment and explore the relationship between LAG-3 expression and therapeutic effect.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!